Chronic migraines are a disabling neurological disorder that affects 1.4 to 2.2% of the general population, according to the Headache Journal of Head and Face Pain. These are patients who experience headaches more than 15 days per month, lasting longer than a 3 month period. The overuse of headache medications can be a real problem for these types of patients. OnabotulinumtoxinA (Botox; Allergan Brand) has now been FDA approved for the treatment of migraine headaches. OnabotulinumtoxinA (Botox) has been reported to relieve pain in a variety of conditions, including migraine headaches. In a recent study in Headache Journal of Head and Face Pain, 89% of patients with episodic migraine who were treated with OnabotulinumtoxinA had complete or partial response of their migraine symptoms, including headache. The conclusion of the study was that OnabotulinumtoxinA (Botox) has been found to be effective, safe, and well-tolerated for the prophylaxis of headache in adults with chronic migraines at doses ranging from 155 to 195 units administered across 7 head and neck muscles (corrugators, procerus, frontalis, temporalis, occipitalis, cervical paraspinal and trapezius) every 12 weeks for up to 5 treatment cycles. Dr. Stan Farrell is now using Botox for the treatment of chronic migraines, headaches and TMJ disorders at his Scottsdale practice, AZ-TMJ. www.aztmj.com